{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:01:02Z","timestamp":1792004462820,"version":"4.4.0"},"reference-count":46,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2022,1,10]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:p>Vedolizumab is a gut-selective monoclonal antibody approved for the management of Crohn\u2019s disease and ulcerative colitis. The available data demonstrate a favourable response to dose escalation in patients with primary non-response or secondary loss of response to vedolizumab. While therapeutic drug monitoring has a proven clinical utility for tumour necrosis factor antagonists, the available guidance for therapeutic drug monitoring and dose escalation of vedolizumab is rather limited. The present review proposes a practical algorithm to use vedolizumab trough levels in the management of treatment failure. Therapeutic drug monitoring can differentiate underexposed patients from those with mechanistic failure. Underdosed patients can respond to dose escalation instead of unnecessarily switching to other treatment modalities. We also review the safety and potential cost-effectiveness of vedolizumab dose escalation, the role of antidrug antibodies and the possible applicability of this strategy to subcutaneous vedolizumab.<\/jats:p>","DOI":"10.1136\/flgastro-2021-102032","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T13:25:54Z","timestamp":1643030754000},"page":"430-435","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Proposed pathway for therapeutic drug monitoring and dose escalation of vedolizumab"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7494-1597","authenticated-orcid":false,"given":"Islam Osama","family":"Nassar","sequence":"first","affiliation":[{"name":"Gastroenterology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cheesbrough","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Nabil","family":"Quraishi","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Sharma","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"2025090709002283000_13.5.430.1","unstructured":"Electronic Medicines Compendium (emc) . Entyvio 300 mg powder for concentrate for solution for infusion, summary of product characteristics (SmPC) [online]. Available: https:\/\/www.medicines.org.uk\/emc\/product\/5442\/smpc#gref [Accessed 01 Dec 2021]."},{"key":"2025090709002283000_13.5.430.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"2025090709002283000_13.5.430.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"2025090709002283000_13.5.430.4","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cgh.2018.06.026","article-title":"Loss of response to Vedolizumab and ability of dose intensification to restore response in patients with Crohn's disease or ulcerative colitis: a systematic review and meta-analysis","volume":"17","author":"Peyrin-Biroulet","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090709002283000_13.5.430.5","unstructured":"The National Institute for Health and Care Excellence . Therapeutic monitoring of TNF-alpha inhibitors in Crohn\u2019s disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) Diagnostics guidance [DG22]. Available: https:\/\/www.nice.org.uk\/guidance\/dg22\/chapter\/9-Review [Accessed 01 Dec 2021]."},{"key":"2025090709002283000_13.5.430.6","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13243"},{"key":"2025090709002283000_13.5.430.7","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40262-017-0546-0","article-title":"A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of Vedolizumab","volume":"56","author":"Rosario","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2025090709002283000_13.5.430.8","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21896"},{"key":"2025090709002283000_13.5.430.9","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/ecco-jcc\/jjx021","article-title":"Exposure-efficacy relationships for Vedolizumab induction therapy in patients with ulcerative colitis or Crohn's disease","volume":"11","author":"Rosario","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2025090709002283000_13.5.430.10","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.26392"},{"key":"2025090709002283000_13.5.430.11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316023"},{"key":"2025090709002283000_13.5.430.12","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s10620-019-05570-1","article-title":"Vedolizumab concentrations are associated with long-term endoscopic remission in patients with inflammatory bowel diseases","volume":"64","author":"Yarur","year":"2019","journal-title":"Dig Dis Sci"},{"key":"2025090709002283000_13.5.430.13","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14548"},{"key":"2025090709002283000_13.5.430.14","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/apt.15484","article-title":"Systematic review with meta-analysis: association between vedolizumab Trough concentration and clinical outcomes in patients with inflammatory bowel diseases","volume":"50","author":"Singh","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090709002283000_13.5.430.15","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818772786","article-title":"Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions","volume":"11","author":"Ward","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"2025090709002283000_13.5.430.16","first-page":"280","article-title":"Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease","volume":"65","author":"Pugliese","year":"2019","journal-title":"Minerva Gastroenterol Dietol"},{"key":"2025090709002283000_13.5.430.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-019-1323-8","article-title":"Vedolizumab Trough level monitoring in inflammatory bowel disease: a state-of-the-art overview","volume":"17","author":"Pouillon","year":"2019","journal-title":"BMC Med"},{"key":"2025090709002283000_13.5.430.18","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/ecco-jcc\/jjz029","article-title":"Vedolizumab Trough levels and histological healing during maintenance therapy in ulcerative colitis","volume":"13","author":"Pouillon","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2025090709002283000_13.5.430.19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/jgh.14584","article-title":"Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients","volume":"34","author":"Van den Berghe","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"2025090709002283000_13.5.430.20","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.cgh.2016.11.023","article-title":"Association between low Trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months","volume":"15","author":"Williet","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090709002283000_13.5.430.21","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315766"},{"key":"2025090709002283000_13.5.430.22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1177\/2050640619873784","article-title":"Early vedolizumab Trough levels predict treatment persistence over the first year in inflammatory bowel disease","volume":"7","author":"Guidi","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"2025090709002283000_13.5.430.23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/apt.15113","article-title":"Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation","volume":"49","author":"Osterman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090709002283000_13.5.430.24","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.3390\/jcm9103142","article-title":"Vedolizumab serum Trough concentrations and response to dose escalation in inflammatory bowel disease","volume":"9","author":"Vaughn","year":"2020","journal-title":"J Clin Med"},{"key":"2025090709002283000_13.5.430.25","first-page":"A69","article-title":"Vedolizumab dose escalation as a way of Recapturing response in patients with inflammatory bowel disease","volume":"67","author":"Birdi","year":"2018","journal-title":"Gut"},{"key":"2025090709002283000_13.5.430.26","first-page":"400","article-title":"Long-Term efficacy of vedolizumab for ulcerative colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2025090709002283000_13.5.430.27","first-page":"412","article-title":"Long-Term efficacy of Vedolizumab for Crohn's disease","volume":"11","author":"Vermeire","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2025090709002283000_13.5.430.28","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1053\/j.gastro.2018.05.039","article-title":"Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease","volume":"155","author":"Dulai","year":"2018","journal-title":"Gastroenterology"},{"key":"2025090709002283000_13.5.430.29","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/apt.15609","article-title":"A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease","volume":"51","author":"Dulai","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090709002283000_13.5.430.30","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-020-00518-0","article-title":"Comparison of the ELISA and ECL assay for vedolizumab anti-drug antibodies: assessing the impact on pharmacokinetics and safety outcomes of the phase 3 gemini trials","volume":"23","author":"Wyant","year":"2020","journal-title":"Aaps J"},{"key":"2025090709002283000_13.5.430.31","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1097\/MIB.0000000000001255","article-title":"Antibodies toward vedolizumab appear from the first infusion onward and disappear over time","volume":"23","author":"Bian","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2025090709002283000_13.5.430.32","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.cgh.2017.11.050","article-title":"Association of vedolizumab level, anti-drug antibodies, and \u03b14\u03b27 occupancy with response in patients with inflammatory bowel diseases","volume":"16","author":"Ungar","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090709002283000_13.5.430.33","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090709002283000_13.5.430.34","unstructured":"Joint Formulary Committee. British National Formulary London: BMJ Group and Pharmaceutical Press . Vedolizumab. Available: https:\/\/bnf.nice.org.uk\/drug\/vedolizumab.html [Accessed 01 Dec 2021]."},{"key":"2025090709002283000_13.5.430.35","unstructured":"Exeter Clinical Laboratory International . Vedolizumab drug levels. Available: https:\/\/www.exeterlaboratory.com\/test\/vedolizumab-drug-levels\/ [Accessed 10 Dec 2021]."},{"key":"2025090709002283000_13.5.430.36","unstructured":"National Institute for Health and Care Excellence . Vedolizumab for treating moderately to severely active ulcerative colitis, technology appraisal guidance [TA342], 2015. Available: https:\/\/www.nice.org.uk\/guidance\/ta342"},{"key":"2025090709002283000_13.5.430.37","unstructured":"Scottish Medicines Consortium . Vedolizumab 300mg powder for concentrate for solution for infusion (Entyvio\u00ae) SMC No. 1064\/15. Available: https:\/\/www.scottishmedicines.org.uk\/media\/2472\/vedolizumab_entyvio_final_june_2015_for_website.pdf [Accessed 13 Jul 2015]."},{"key":"2025090709002283000_13.5.430.38","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1093\/ecco-jcc\/jjy222.614","article-title":"P490 a vedolizumab population pharmacokinetic model including intravenous and subcutaneous formulations for patients with ulcerative colitis","volume":"13","author":"Rosario","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2025090709002283000_13.5.430.39","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation for ulcerative colitis: results of the visible trial","volume":"68","author":"Sandborn","year":"2019","journal-title":"Gut"},{"key":"2025090709002283000_13.5.430.40","unstructured":"ClinicalTrials.gov . A study of long-term effects of vedolizumab subcutaneous in adults with ulcerative colitis and Crohn\u2019s disease. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02620046"},{"key":"2025090709002283000_13.5.430.41","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"2025090709002283000_13.5.430.42","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/ibd\/izy304","article-title":"Fecal calprotectin responses following induction therapy with vedolizumab in moderate to severe ulcerative colitis: a post hoc analysis of gemini 1","volume":"25","author":"Reinisch","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2025090709002283000_13.5.430.43","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.cgh.2018.04.040","article-title":"Evidence to support monitoring of vedolizumab Trough concentrations in patients with inflammatory bowel diseases","volume":"16","author":"Dreesen","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090709002283000_13.5.430.44","doi-asserted-by":"crossref","first-page":"S358","DOI":"10.14309\/01.ajg.0000704908.05410.59","article-title":"S0715 Longer Duration of Response With Proactive Therapeutic Drug Monitoring for Infliximab but Not for Vedolizumab Treatment in Patients With Inflammatory Bowel Disease","volume":"115","author":"Al Yassin","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2025090709002283000_13.5.430.45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/ibd\/izaa073","article-title":"A systematic review on cost-effectiveness analyses of therapeutic drug monitoring for patients with inflammatory bowel disease: from immunosuppressive to anti-TNF therapy","volume":"27","author":"Yao","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2025090709002283000_13.5.430.46","first-page":"1079","article-title":"Therapeutic drug monitoring is more cost-effective than a clinically based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multicentre study","volume":"12","author":"Guidi","year":"2018","journal-title":"J Crohns Colitis"}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/flgastro-2021-102032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:00:32Z","timestamp":1757260832000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/flgastro-2021-102032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,8,5]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/flgastro-2021-102032"],"URL":"https:\/\/doi.org\/10.1136\/flgastro-2021-102032","relation":{},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"value":"2041-4137","type":"print"},{"value":"2041-4145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]}}}